Trial Profile
A 2-stage, Phase 1/2a Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat (Phase 1)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs CBL-514 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Caliway Biopharmaceuticals Australia
- 02 Dec 2020 Status changed from recruiting to completed.
- 05 Dec 2018 Planned number of patients changed from 36 to 40.
- 05 Dec 2018 Planned initiation date changed from 1 Jul 2018 to 11 Dec 2018.